rasagiline has been researched along with Skin Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, EB; Calingaert, B; Gordon, MF; Johannes, CB; Kaplan, S; Kaye, JA; Saltus, CW | 1 |
| Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J | 1 |
2 other study(ies) available for rasagiline and Skin Neoplasms
| Article | Year |
|---|---|
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.
Topics: Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Indans; Male; Medicare; Melanoma; Parkinson Disease; Retrospective Studies; Skin Neoplasms; United States | 2022 |
Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Female; Humans; Indans; Melanoma; Mice; Mice, Nude; Monoamine Oxidase Inhibitors; Skin Neoplasms; Tissue Distribution; Transdermal Patch; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |